[GEK-NEU: triply washed erythrocytes from O Rh-negative and CMV-seronegative donors withdrawn less than 4 days before transfusion into newborn infants at risk].
Explore the source record for details and available documents.
Antibodies, Viral↗
Biomedical subjects
U Diekamp
Publications and source records attributed to U Diekamp.
Postsurgical adjuvant chemotherapy: a review.
Explore the source record for details and available documents.
Aged↗
"CAMP" combination chemotherapy for unresectable non-oat cell bronchogenic carcinoma.
Experience with camp chemotherapy of 84 unresectable non-oat cell lung cancer patients is described. Fourteen (27%) of 51 patients with measurable lesions responded (3 CR, 11 PR) for a median response duration of 5 months with a range of 1 to 19+ months. Median survival of responders was 370 days, but response was not independent of performance status. Survival of patients without measurable lesions was less favorable than that of even nonresponders, suggesting prediction of response to CAMP by site of metastasis. Preliminary results of a randomized prospective trial of the CAMP combination versus CCNU as a single agent for patients with good performance status fail to show a difference in survival.
Antineoplastic Agents↗
Breast cancer in young women.
Explore the source record for details and available documents.
Adolescent↗
[The behavior of factor VIII activity during radiotherapy of gynecologic carcinomas].
Explore the source record for details and available documents.
Adult↗
Heterogeneity of u antibodies.
Explore the source record for details and available documents.
Antibody Specificity↗
Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: a randomized trial.
A randomized control trial was performed in good performance status patients with unresectable non-small cell lung cancer to test a strategy of early aggressive combination chemotherapy (CAMP [cyclophosphamide, doxorubicin, methotrexate, and procarbazine]) versus a strategy of delaying such treatment until clinical deterioration. Thirty-seven patients received immediate CAMP and 35 patients received initial low-dose single-agent CCNU (CAMP was postponed). Immediate CAMP therapy produced an objective response rate of 44% in patients with measurable lesions, and CCNU produced none. Median survival was 193 days for the immediate-CAMP group and 175 days for the postponed-CAMP group (P = 0.26). Measures of quality of life were made and no difference emerged between the two treatment strategies. This trial failed to show substantial benefit from immediate combination chemotherapy in minimally symptomatic patients with non-small cell lung cancer.
Antineoplastic Agents↗